Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Recent data suggests people taking GLP-1 drugs may develop colorectal cancer less often than those taking aspirin, a ...
Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular ...
A growing body of research is describing the anti-inflammatory and immunomodulatory benefits of exercise, according to data ...
Sunny, a Labrador retriever, was successfully treated with VetStem Cell Therapy for multiple orthopedic injuries. We ...
India is home to nearly 90 million people with T2DM , with an estimated 39.4 million remaining undiagnosed. Recent estimates ...
Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
Downtown Chicago’s premier integrative medicine clinic offers a clinically superior alternative to standalone dry ...
Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...
The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent ...
A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results